Mylan Launches Hulio (adalimumab, biosimilar) in EU for Autoimmune Diseases

 Mylan Launches Hulio (adalimumab, biosimilar) in EU for Autoimmune Diseases

Mylan Launches Hulio (adalimumab, biosimilar) in EU for Autoimmune Diseases

Shots:

  • AbbVie’s Humira biosimilar, Hulio received EU approval in Sep 2018, reviewing CHMP approval which included biosimilarity data regarding analytical, functional, clinical and immunogenicity of Hulio with Humira
  • The launch of Hulio post EU approval is available in all 28 EU member countries including Norway, Iceland and Liechtenstein. In July, 2018 Humira had brand sales of ~$4.3B in EU
  • Adalimumab IV is a TNFi indicated for treatment of autoimmune diseases. In H1’18, Mylan and Kyowa Kirin entered into a collaboration for Hulio’s commercialization in EU

Click here to read full press release/ article | Ref: Mylan| Image: Investor Business Daily

 

Shiwani Sharma

Shiwani Sharma was Senior Editor at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post